TG Therapeutics, Inc. (MHA) Announces Clinical and Pre-Clinical Poster Presentations for TG-1101 and TGR-1202 at the European Hematology Association Meeting in Stockholm, Sweden
6/17/2013 8:50:51 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
NEW YORK, June 17, 2013 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (Nasdaq:TGTX), an innovative, clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of cancer and other underserved therapeutic needs, today announced two clinical posters on ublituximab (TG-1101) and one pre-clinical poster on TGR-1202 were presented at the European Hematology Association (EHA) Meeting which was held in Stockholm, Sweden. The poster presentations were as follows:
Help employers find you! Check out all the jobs and post your resume.
comments powered by